In the past four months, ICP-UCR researchers used various SARS-CoV-2 virus proteins to immunize six donated horses and thereby induce the immune system of these animals to produce specific antibodies.
In total, there were four immunizations with different combinations of SARS-CoV-2 proteins that, at no time, harmed the health of the animals.
Later, the scientists extracted the blood and separated the blood cells from their liquid part, called blood plasma, which contains the antibodies.
The antibodies were then purified in the pharmaceutical plant of the UCR Clodomiro Picado Institute and, finally, they were used to formulate and package the new medicine, which is an injectable liquid.
“Among the proteins selected for immunization is the S1 protein, which is the viral protein that binds to the cellular receptor. Also E and M proteins, as a recombinant construct, and nucleocapsid N protein ”, commented Dr. Guillermo León, coordinator of the Industrial Division of ICP-UCR, in previous statements.
But that is not the only positive news. The formulations also successfully passed the sterility tests carried out by the Pharmaceutical Analysis and Advisory Laboratory (Layafa-UCR), in which the serum was found to have the required sterility to be applied to patients.
“The quality test carried out at Layafa-UCR showed the absence of aerobic bacteria, fungi and yeasts, so it can be concluded that the sample analyzed is harmless (safe) from the point of view of microbial contamination,” said Dra. Jeimy Blanco Barrantes, Laboratory coordinator.